Catalyst Wire Dossier Catalyst Wire Dossier

XEMBIFY

intravenous immunoglobulin (IVIG) · Grifols Therapeutics LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for XEMBIFY, covering 2026-04-13 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy [Phase 3]

See pricing